首页> 外国专利> Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen

Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen

机译:孕激素和雌激素口服联合药物制剂的多相避孕方案

摘要

A method for contraception includes administering to a female daily, during a time period of 21 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein the drug formulation is administered in a biphasic dosing regimen comprising a 14 day phase and a 7 day phase, wherein doses of each of the norethindrone acetate and EE in the second phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the norethindrone acetate and EE administered during the first phase of the regimen, wherein the norethindrone acetate dose in the first phase is 1000 mcg and in the second phase is 1500 mcg, wherein the EE dose in the first phase is 20 mcg and in the second phase is 30 mcg, and wherein the biphasic dosing regimen is followed by 7 days without norethindrone acetate and EE administration.
机译:避孕方法包括在连续21天的时间段内每天向女性给药醋酸炔诺酮和乙炔雌二醇(EE)的口服组合药物制剂,其中该药物制剂以包括14天的双相给药方案给药阶段和7天阶段,其中与该方案第一阶段给药的相应剂量的乙酸炔诺酮和EE的相应剂量相比,该方案第二阶段中的乙酸炔诺酮和EE的剂量分别增加了预定的剂量增量,其中乙酸炔诺酮在第一阶段的剂量为1000 mcg,在第二阶段的剂量为1500 mcg,其中第一阶段的EE剂量为20 mcg,第二阶段的EE剂量为30 mcg,并且遵循双相给药方案不用乙酸炔诺酮和EE给药7天。

著录项

  • 公开/公告号US10111887B2

    专利类型

  • 公开/公告日2018-10-30

    原文格式PDF

  • 申请/专利权人 ARSTAT INC.;

    申请/专利号US201815926407

  • 发明设计人 ARKADY RUBIN;

    申请日2018-03-20

  • 分类号A61K31/56;A61K31/567;A61K9;

  • 国家 US

  • 入库时间 2022-08-21 13:05:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号